MedTrace Logo

Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141

NCT06235437 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2026-01-07

No results posted yet for this study

Summary

This is a Phase I study designed to evaluate if ASD141 is safe, tolerable, and efficacious in participants with advanced solid tumors.

Conditions

  • Metastatic Solid Tumor

Interventions

BIOLOGICAL

ASD141

Subjects will receive one of 8 dose levels of ASD141.

Sponsors & Collaborators

  • Ascendo Biotechnology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yu-Min Yeh, M.D. PhD. · National Cheng-Kung University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-29
Primary Completion
2026-12-31
Completion
2027-12-31
FDA Drug
Yes

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06235437 on ClinicalTrials.gov